A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO

Prior treatment

• Have had previous thermal subfoveal laser therapy in the study eye
• Have had previous photodynamic therapy with Visudyne in the study eye
  • Key BRVO-specific Exclusion Criteria

Other illness

• History of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of Screening
• Have macular edema in the study eye considered to be secondary to a cause other than BRVO (eg, diabetic macular edema, NVAMD, Irvine-Gass syndrome)

Lab values

• Currently using drugs with known retinal toxicity (e.g., Hydroxychloroquine, pentosan polysulfate sodium, and amiodarone)
  • Key NVAMD-specific Exclusion Criteria

Other

• Key General Exclusion Criteria
• Pregnant or breastfeeding
• Have had Yttrium-Aluminum Garnet (YAG) laser capsulotomy in the study eye within 90 days of Screening
• Have active iris or angle neovascularization or neovascular glaucoma in the study eye

• Key General Inclusion Criteria
• Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity
  • Key Neovascular Age-related Macular Degeneration (NVAMD)-specific Inclusion Criteria
• Be ≥ 50 years of age
• Have treatment naive subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) or juxtafoveal/extrafoveal CNV with foveal involvement
• For participants who are treatment naïve for NVAMD, the diagnosis must have been made within 21 days prior to the Day 1 study treatment
  • Key Incomplete Responder (IR) NVAMD-specific Inclusion Criteria
• Be ≥ 50 years of age
• Have subfoveal CNV secondary to AMD or juxtafoveal/extrafoveal CNV with foveal involvement at initial screening
• For participants who are treatment experienced for NVAMD, the diagnosis must have been made within 90 days prior to the Screening Visit 2
  • Key Branch Retinal Vein Occlusion (BRVO)-specific Inclusion Criteria
• Be diagnosed with BRVO in the study eye
• Have a decrease in vision in the study eye determined by the Investigator to be primarily the result of BRVO
• Be treatment naïve with vision loss in the study eye and have center-involving macular edema diagnosed within 9 months of Screening